Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | EVP, Chief Technology Officer | November 11, 2019 | November 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date November 11, 2019 · Filed November 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,977 |
Reported balance
After 2019-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-11 · Sale · Disposed 339 · Balance 1,977 F1: This number includes unvested restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This number includes unvested restricted stock units previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 13, 2019 22:24 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 339 | $118.27 | $40,093.53 |
DisclosureSEC source: 0001127602-19-032647 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,977 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 832 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-19-027768 · form4.xml · derivative · entry 3 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,498 Underlying: Common Stock · 832 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 657 | $133.73 | $87,860.61 |
DisclosureSEC source: 0001127602-19-027768 · form4.xml · nonDerivative · entry 2 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,316 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 832 | $93.52 | $77,808.64 |
DisclosureSEC source: 0001127602-19-027768 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 69 | $109.37 | $7,546.53 |
DisclosureSEC source: 0001127602-19-021563 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,141 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,451 | $0.00 Strike: $98.03 | $0.00 |
DisclosureSEC source: 0001127602-19-018739 · form4.xml · derivative · entry 2 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,451 Underlying: Common Stock · 4,451 shares Expires 2026-05-14 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018739 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,210 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 3,330 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020843 · form4.xml · derivative · entry 2 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330 Underlying: Common Stock · 3,330 shares Expires 2025-06-11 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 935 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020843 · form4.xml · nonDerivative · entry 1 Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.